Risk of intracranial haemorrhage with tipranavir

Boehringer Ingelheim has issued a safety warning for its protease inhibitor Aptivus (tipranavir) advising of the risks of intracranial haemorrhage that may be associated with use of the product.

The safety warning was issued following reports of 14 cases of intracranial haemorrhage, including eight fatalities, among 6,840 HIV-infected patients receiving Aptivus in clinical trials.

Although many of the patients had other conditions or were receiving concomitant medication that could have contributed to the intracranial haemorrhage and patients with advanced HIV disease are at an increased risk of suffering such an event, the role of tipranavir cannot be excluded.

Consequently, healthcare professionals are being advised that Aptivus should be used with caution in patients who may be at an increased risk of bleeding from trauma, surgery or other medical conditions, or who are receiving concomitant medication that is known to increase the risk of bleeding.

Further information: Boehringer Ingelheim Ltd, Ellesfield Avenue, Bracknell, Berkshire RG12 8YS. Tel: (01344) 424600.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...

An older man in a blue shirt and beige trousers leans forward on a sofa rubbing his painful lower back. Promoted
MIMSconnect

Established muscle relaxant offers new approach to managing back pain

Sponsored by Mibe Pharma

A muscle relaxant that has been used for decades outside the UK may provide an alternative to current treatments for low back pain, explains Dr Sunny Nayee, consultant in anaesthesia and pain medicine at Imperial College NHS Healthcare Trust.

Sponsored by Mibe Pharma UK Ltd. UK/MYO/21/044; December 2021.

Click here to view prescribing information for Myopridin® (pridinol mesilate)